Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib and bevacizumab in glioblastoma multiforme
NCT02386826Phase 1Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2015
- Primary completion
- Jul 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of capmatinib in glioblastoma multiforme (GBM) and Gliosarcoma (GS), sponsored by SCRI Development Innovations. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Sep 2015; status: completed.
02
Drugs
capmatinib
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02386826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386826.